BioWorld Asia

June 9, 2004

IDM Seeking EUR92 Million In IPO To Fund Programs In Cancer

PARIS - Immuno-Designed Molecules SA proposed an IPO on the Nouveau Marche of the Euronext stock exchange in Paris last week, offering 8.1 million shares at €10.50 to €12.20 per share. (BioWorld International) Read More

UK Researchers Discover Mutant Gene's Role In Type II Diabetes

Countries Throughout The World Promoting Biotech Development

UK Officials Continue Campaign To Improve Biotech Environment

Serono Abandons Emfilermiun, Setting Back Amrad Program

Private Australian Companies Cerylid, Kinacia Merge Efforts

IQ Corp., U.S. Navy Enter Deal To Develop Biodefense Agents

Shareholders Accept Deal To Close Shop At PPL Therapeutics

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...